Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280566 · ClinicalTrials.gov registry record · Phase 3
Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 584
- Enrollment target
NCT00280566 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 584 participants.
The verdict
NCT00280566, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 584 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8 consecutive weeks of symptom improvement on the regimen.
Interventions
- DRUG Placebo
- DRUG Ziprasidone Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 584 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280566
The ClinicalTrials.gov registry entry for NCT00280566 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 584 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00280566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00280566 about?
NCT00280566 is a clinical study titled "Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)". The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8 consecutive weeks of symptom improvement on the regimen.
What is the current status of trial NCT00280566?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 584 participants. The study started on 2005-12. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00280566?
The interventions under investigation include: Placebo (DRUG), Ziprasidone Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT00280566?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.